Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

79 results about "Acquired Passive Immunity" patented technology

Maternal passive immunity is a type of naturally acquired passive immunity, and refers to antibody-mediated immunity conveyed to a fetus or infant by its mother. Naturally acquired passive immunity can be provided during pregnancy, and through breastfeeding.

Compositions for the Prevention and Treatment of Smallpox

The present invention relates to improved compositions for the prevention and treatment of smallpox, and in particular to the use of compositions containing an antibody that binds to an epitope found on the MV form of the smallpox virus and an antibody that binds to an epitope found on the EV form of the smallpox virus. The invention relates to such compositions, especially to non-blood derived antibody compositions, such as chimeric or humanized antibodies, and to methods for their use in imparting passive immunity against smallpox infection to individuals at risk of smallpox virus infection or who exhibit smallpox.
Owner:MACROGENICS INC

Preparation method of C-type clostridium perfringens toxin vaccine of piglet red dysentery

The invention relates to a preparation method of a C-type clostridium perfringens toxin vaccine of piglet red dysentery. The preparation method comprises the following steps of inoculating strains NCTC (National Collection Of Type Culture) 3180 of the C-type clostridium perfringens into a blood plate culture medium for carrying out anaerobic cultivation for 36 hours at 37 DEG C; carrying out shake cultivation on the culture by adopting a homemade toxin-producing medium (100 ml of PBS (Phosphate Buffer Solution), 2g of peptones, 1g of dextrin, 2g of yeast extracts, and 1.2g of L- arginine) under an anaerobic environment; inactivating the culture, filtering and adding an adjuvant to prepare the C-type clostridium perfringens toxin vaccine of the piglet red dysentery. During a using process, intramuscular injection is respectively adopted once a month and half a month before the delivery of a sow, wherein the dosage is 5-10 ml at a time. The C-type clostridium perfringens toxin vaccine of the piglet red dysentery is used for the sow at the later immunological gestation period, so that piglets obtain passive immunity through colostrums, and therefore, piglet red dysentery can be prevented. Moreover, the C-type clostridium perfringens toxin vaccine of the piglet red dysentery can be used for preventing sheep struck and calf enterotoksemia, so that the popularization of the C-type clostridium perfringens disease can be effectively controlled.
Owner:SHANDONG AGRICULTURAL UNIVERSITY

Anti-Foot-and-Mouth Disease Virus Monoclonal Antibody and Its Recognized Epitope and Application

ActiveCN102277333AGood passive immunityImprove immunityImmunoglobulins against virusesMicroorganism based processesIn vivoNeutralization epitope
The invention discloses a monoclonal antibody resisting the foot and mouth disease virus, epitope identified by the monoclonal antibody, as well as application of the monoclonal antibody, and belongs to the field of prevention and control of the foot and mouth disease. The hybridoma cell line capable of excreting the neutralizing monoclonal antibody resisting O-type FMDV (foot and mouth disease virus) has a microbial preservation number of CGMCC (China General Microbiological Culture Collection Center) 2691. The invention also discloses amino acid sequences of linear neutralization epitope of O-type FMDV VP1 protein identified by the monoclonal antibody respectively. In-vitro neutralization tests and in-vivo animal protection tests prove that: the monoclonal antibody disclosed by the invention has excellent passive immune effect, can be applied to emergency prevention of the foot and mouth disease, and plays an excellent immune effect to the passive immunity of the foot and mouth disease.
Owner:HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI

Methods and compositions for promoting immunopotentiation

This invention discloses immunopotentiating agents which stimulate an immune response. These agents are categorized into single agents that act directly, adjuvants added concurrently with the agents, or heteroconjugates. Heteroconjugate agents elicit or enhance a cellular or humoral immune response which may be specific for an epitope contained within an amino acid sequence. Enhanced hematopoieses by bone marrow stem cell recruitment was also a result of administering some of these agents. Examples of immunopotentiating agents include monoclonal antibodies and proteins derived from microorganisms (e.g., enterotoxins) which activate T cells. One method of treatment disclosed uses only the immunopotentiating agent to stimulate the immune system. Another uses adjuvants in combination with the agent. A third method employs heteroconjugates. Heteroconjugates comprise: (a) an immunopotentiating protein which is characterized as having an ability to stimulate T cells; and (b) a second protein having an amino acid sequence which includes an epitope against which a cellular or humoral response is desired. This invention also relates to a method of preparing the heteroconjugate, and to a method of stimulating the immune system in vivo in a novel way. One route of stimulation is to activate T cells, in some instances, specific subsets of T cells, by administering heteroconjugates containing an immunopotentiating protein and a second protein, to mammals. For this method of treatment, the second protein in the heteroconjugate is derived from abnormal or diseased tissue, or from an infectious agent; alternatively, the second protein is produced synthetically by standard methods of molecular biology. Sources of the second protein include tumors, viruses, bacteria, fungi, protozoal or metozoal parasites. Monoclonal antibodies or T cells prepared from mammals whose immune systems have responded to administration of the heteroconjugate may be produced and administered to induce passive immunity. A method of preparing a hybridoma which secretes said monoclonal antibodies and use of these monoclonal antibodies and T cells, are also disclosed. This invention is also directed to a vaccine comprising the heteroconjugate.
Owner:BLUESTONE JEFFERY A

Preparation method and applications of anti-pseudorabies virus pig origin monoclonal antibody

The invention belongs to the field of gene engineering, and discloses a preparation method and applications of an anti-pseudorabies virus pig origin monoclonal antibody. The preparation method comprises following steps: positive hybridoma cells capable of realizing stable secretion of anti-pseudorabies virus (PRV) glycoprotein monoclonal antibodies are screened; secretion of the monoclonal antibodies is carried out; enlarge culture is carried out; enrichment, purification, and sequencing are carried out; design of corresponding specific primers is carried out, pig origin modification is carried out, cloning is carried out using a virus gene carrier or a non-virus gene carrier (including plasmid DNA and minicircle DNA), large scale production of different pig origin monoclonal antibodies iscarried out using insect cells or CHO cell fermentation, or the above pig origin monoclonal antibody gene carrier is introduced into pigs; injection, or feeding through nasal feeding and spraying areadopted for neutralization of pseudorabies virus with the anti-pseudorabies virus pig origin monoclonal antibodies, so that passive immunity is adopted for purifying of pseudorabies virus positive pig farms, and preventing and treating of porcine pseudorabies.
Owner:SHENZHEN JASON INTELLIGENT BIOTECH CO LIMLTED PRC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products